Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

Author： Lepen C.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.23, Iss.9, 2003-01, pp. : 571-581

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo   Hartung Hans-Peter   Kurukulasuriya Nuwan C   Greenberg Steven J   Scaramozza Matthew  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Interferons in Relapsing-Remitting Multiple Sclerosis: Are There Benefits from Long-Term Use?

By Oscar Fernández  

CNS Drugs, Vol. 18, Iss. 15, 2004-01 ,pp. : 1057-1070

Adis International

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon- -1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

Drugs, Vol. 65, Iss. 9, 2005-01 ,pp. : 1295-1312

Adis International

Access to resources Recommend Favorite

Interferon- -1b: A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By McCormack P.L.   Scott L.J.  

CNS Drugs, Vol. 18, Iss. 8, 2004-01 ,pp. : 521-546

Adis International

Access to resources Recommend Favorite

The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

By  

Current Neuropharmacology, Vol. 12, Iss. 3, 2014-05 ,pp. : 256-268

Bentham Science Publishers

Access to resources Recommend Favorite